RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Clinical and economic burden of HER2-positive breast cancer recurrence in the US
A literature review
Masaquel, C., Hurley, D., Barnett, B., Krieger, T., Pearson, I., Copley-Merriman, C., Kaye, J. A., & Moy, B. (2018). Clinical and economic burden of HER2-positive breast cancer recurrence in the US: A literature review. Cancer Research, 78(4 Supplement), P3-10-14-P3-10-14. https://doi.org/10.1158/1538-7445.SABCS17-P3-10-14
Abstract P3-10-14 This search identified few studies on patients with early stage HER2+ BC and suggest that future studies are warranted. * After adjuvant therapy, the 10-year risk of recurrence can be up to 22%. The clinical and economic burden of early stage HER2+ BC remains substantial. * Recurrence in women with BC, regardless of HER2 status, is associated with high costs and a likelihood of decreased QOL. * Therefore, there is an unmet medical need in early stage HER2+ BC for new therapies that can reduce the risk of recurrence and the consequent clinical and economic burden of advanced disease. * Economic studies on the cost of recurrence should be conducted given the higher cost of recently approved HER2+ targeted therapies in the metastatic setting.
